Company

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used for the therapy and care of critically and chronically ill patients.

About Us

Inspiring Story - Living on Parenteral Nutrition

Our Business Fields

Locations Worldwide

November 2, 2023

#FutureFresenius continues to provide positive momentum: Fresenius delivers strong third quarter performance and improves operating earnings outlook

Fresenius Kabi launches Tyenne®*, the first approved tocilizumab biosimilar in the European Union

Supporting Conscious Choices in Nutritional Care

Gastrointestinal dysfunction study wins inaugural ESICM Clinical Nutrition Award

Fresenius Kabi and Formycon announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

Tyenne®*, Fresenius Kabi’s tocilizumab biosimilar, receives European Commission approval

Fresenius Kabi recognized as a Top Employer in 2023

Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi

JUMPstart Clinical Nutrition Award winner announced at ESPEN congress

Fresenius Kabi and Lupagen enter into strategic development and supply agreement

#FutureFresenius continues to provide positive momentum: Fresenius delivers strong third quarter performance and improves operating earnings outlook

Fresenius Kabi launches Tyenne®*, the first approved tocilizumab biosimilar in the European Union

Supporting Conscious Choices in Nutritional Care

Gastrointestinal dysfunction study wins inaugural ESICM Clinical Nutrition Award

Fresenius Kabi and Formycon announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

Tyenne®*, Fresenius Kabi’s tocilizumab biosimilar, receives European Commission approval

Fresenius Kabi recognized as a Top Employer in 2023

Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi

JUMPstart Clinical Nutrition Award winner announced at ESPEN congress

Fresenius Kabi and Lupagen enter into strategic development and supply agreement

History

Quality Management

MNI - Optimal Nutrition Care For All

Get an overview of all Fresenius Kabi activities

Company

November 2, 2023

#FutureFresenius continues to provide positive momentum: Fresenius delivers strong third quarter performance and improves operating earnings outlook

November 1, 2023

Fresenius Kabi launches Tyenne®*, the first approved tocilizumab biosimilar in the European Union

October 31, 2023

Supporting Conscious Choices in Nutritional Care

October 25, 2023

Gastrointestinal dysfunction study wins inaugural ESICM Clinical Nutrition Award

September 29, 2023

Fresenius Kabi and Formycon announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

September 19, 2023

Tyenne®*, Fresenius Kabi’s tocilizumab biosimilar, receives European Commission approval

September 15, 2023

Fresenius Kabi recognized as a Top Employer in 2023

September 14, 2023

Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi

September 13, 2023

JUMPstart Clinical Nutrition Award winner announced at ESPEN congress

August 24, 2023

Fresenius Kabi and Lupagen enter into strategic development and supply agreement

November 2, 2023

#FutureFresenius continues to provide positive momentum: Fresenius delivers strong third quarter performance and improves operating earnings outlook

November 1, 2023

Fresenius Kabi launches Tyenne®*, the first approved tocilizumab biosimilar in the European Union

October 31, 2023

Supporting Conscious Choices in Nutritional Care

October 25, 2023

Gastrointestinal dysfunction study wins inaugural ESICM Clinical Nutrition Award

September 29, 2023

Fresenius Kabi and Formycon announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

September 19, 2023

Tyenne®*, Fresenius Kabi’s tocilizumab biosimilar, receives European Commission approval

September 15, 2023

Fresenius Kabi recognized as a Top Employer in 2023

September 14, 2023

Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi

September 13, 2023

JUMPstart Clinical Nutrition Award winner announced at ESPEN congress

August 24, 2023

Fresenius Kabi and Lupagen enter into strategic development and supply agreement